Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients - Scorecard - MDSpire

Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients

  • By

  • H. Habibullah

  • M. Alotaibi

  • H. Almarzouki

  • Z. Mulla

  • M. Elbaiomy

  • R. Alahmadi

  • A. Ahmed

  • Y. Bahadur

  • R. Ujaimi

  • E. Senan

  • M. Attar

  • A. Bamakhramah

  • H. Altoukhi

  • H. Muamenah

  • O. Iskanderani

  • R. Garout

  • J. Alturkistani

  • H. Hijazi

  • Z. Jastaniah

  • June 10, 2026

  • 0 min

Share

Clinical Scorecard: Enhancing Treatment Efficacy with Fewer Sessions: A Multi-Institutional Analysis of Fast-Forward Fractionation and Dosimetric Influences on Toxicity in Breast Cancer Patients

At a Glance

CategoryDetail
Condition
Key MechanismsUltra-hypofractionated radiotherapy (RT) with 26 Gy in 5 fractions (source needed)
Target Population
Care Setting

Key Highlights

  • Remove 'Optimizing dosimetric factors may reduce adverse effects' unless directly supported.

Guideline-Based Recommendations

Diagnosis

    Management

    • Adjuvant radiotherapy with 26 Gy in 5 fractions (source needed)

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        100 breast cancer patients treated with whole-breast adjuvant radiotherapy

        Breast pain and dermatitis correlated with dosimetric factors and BMI

        Clinical Best Practices

        • Ensure all practices are directly supported by the source.

        Related Resources & Content

        Original Source(s)

        Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients

        • by H. Habibullah, M. Alotaibi, H. Almarzouki, Z. Mulla, M. Elbaiomy, R. Alahmadi, A. Ahmed, Y. Bahadur, R. Ujaimi, E. Senan, M. Attar, A. Bamakhramah, H. Altoukhi, H. Muamenah, O. Iskanderani, R. Garout, J. Alturkistani, H. Hijazi, Z. Jastaniah

        • June 10, 2026

        Related Content

        Management of toxicities from antibody – drug conjugates in breast cancer

        Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study

        ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report